3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
56
Ovarian Neoplasms
35
Carcinoma, Hepatocellular
35
Neoplasms
25
Fallopian Tube Neoplasms
20
Carcinoma, Non-Small-Cell Lung
19
Endometrial Neoplasms
13
Glioblastoma
11
Breast Neoplasms
11
Brain Neoplasms
11
Neoplasm Metastasis
9
Colonic Neoplasms
9
Lung Neoplasms
8
Uterine Cervical Neoplasms
7
Liver Neoplasms
7
Rectal Neoplasms
6
Glioma
6
Biliary Tract Neoplasms
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Peritoneal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bumetanide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unresectable Hepatocellular Carcinoma
×
Bevacizumab
×
90 days
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled